Better Buy: Biogen Inc. vs. Gilead Sciences
Historically, Biogen (NASDAQ: BIIB) has definitely been a better stock than Gilead Sciences (NASDAQ: GILD). Whether you look at the last three, five, 10, 25 years, or even so far in 2017, Biogen has outperformed Gilead.
But for investors, the future matters a whole lot more than the past. Which of these two big biotech stocks is the better pick going forward? Here's how Biogen and Gilead Sciences compare.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Aktie
126,44 €
2,52 %
Die Gilead Sciences Inc Aktie steht ausgezeichnet da: Nur Buy-Einschätzungen und keine Sell-Einschätzungen.
Ein positives, aber moderates Potenzial für Gilead Sciences Inc mit einem Kursziel von 128 € im Vergleich zu 126.44 €.
